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AbstrAct:
We have previously shown that the differential susceptibility of A/J (susceptible) and 
C57BL/6J (B6, resistant) mouse strains to azoxymethane (AOM)-induced colorectal 
cancer (CRC) is controlled by the chromosome 3 locus, Ccs3. We report that A/J 
and B6 mice also show differential susceptibility to colitis-associated colorectal 
cancer (CA-CRC) induced by combined administration of AOM and dextran sulfate. 
This differential susceptibility is not controlled by Ccs3, but is under distinct genetic 
control. Linkage analyses in (A/J x B6)F2 mice detected a major CA-CRC susceptibility 
locus on chromosome 9 (Ccs4) which controls tumor multiplicity and tumor surface 
area. Susceptibility alleles at Ccs4 are inherited in a recessive fashion, with A/J alleles 
being associated with susceptibility. We also detected a second locus on chromosome 
14 that acts in an additive fashion with Ccs4. Strikingly, F2 mice homozygous for A/J 
alleles at both loci (Ccs4 and chromosome 14) are as susceptible to CA-CRC as the 
A/J controls while mice homozygous for B6 alleles are as resistant as the B6 controls, 
thus supporting the role of two interacting loci in this CA-CRC model. This indicates 
that susceptibility to chemically-induced CRC and susceptibility to CA-CRC are under 
distinct genetic control in mice, and probably involve distinct cellular pathways.
INtrODUctION
Colorectal cancer (CRC) is the third most common 
type of cancer-related deaths worldwide [1]. CRC 
etiologies can be classified as hereditary (10%), sporadic 
(<90%)  or  inflammatory  (1-2%)  [2].  Hereditary  CRCs 
arise due to highly penetrant germline mutations [3]. The 
two most common syndromes are familial adenomatous 
polyposis (FAP) and hereditary non-polyposis colon 
cancer (HNPCC) that arise due to mutations in the APC 
(Adenomatous polyposis coli) gene and mismatch repair 
genes (MSH2, MLH1, MSH6 and PMS2), respectively. 
Sporadic  CRCs  are  thought  to  have  a  heterogeneous 
etiology,  including  a  combination  of  complex 
environmental  and  genetic  components  [4].  Recently, 
several genome-wide association studies (GWAS) have 
revealed as many as ten common low-penetrance genetic 
variants contributing to sporadic CRC risk: these genes 
or  loci  are  found  on  human  chromosomes  8,  10,  11, 
14, 15, 18, 19 and 20 [5-10]. Inflammation, in the form 
of  the  inflammatory  bowel  diseases  (IBD),  ulcerative 
colitis  (UC)  and  Crohn’s  disease  (CD),  represents  the 
third most common risk factor for CRC after the FAP 
and HNPCC [11]. These colitis-associated (CA) CRCs Oncotarget 2010; 1:  436 - 446 437 www.impactjournals.com/oncotarget
have  many  similar  molecular  alterations  to  sporadic 
CRCs and therefore were originally considered to be 
a subtype of sporadic CRCs. However, the timing and 
frequency of these molecular events differ, which has led 
to speculations that different genes may be responsible 
for sporadic CRC and CA-CRC [2, 11]. Both CD and UC 
are influenced by a variety of environmental and genetic 
factors including low penetrance susceptibility genes. 
To date, GWAS studies point to >30 genetic loci/genes 
for susceptibility to CD and UC, with several shared loci 
involved in the Th-17 response (NOD2, IL23R, IL12B, 
JAK2, STAT3) [12-14]. Allelic differences in the class II 
human leukocyte antigens (HLA) on chromosome 6 are 
associated with both increased and decreased risk of CA-
CRC [15]. Interestingly, loss of heterozygosity (LOH) on 
chromosome 6 has been previously reported as a unique 
feature of CA-CRC, distinguishing it from sporadic CRC 
and UC [16]. 
In  addition  to  human  GWAS  studies,  significant 
contributions  have  been  made  towards  identifying 
tumor susceptibility genes using carcinogen-induced 
mouse models. Sporadic CRC can be modeled through 
repeated administration of the colon-specific carcinogens 
1,2-dimethyhydrazine  (DMH)  or  its  metabolite 
azoxymethane (AOM) [17]. DMH studies in recombinant 
congenic lines derived from BALB/c (resistant) and STS/A 
(sensitive)  progenitors  have  identified  the  Scc1 locus 
(Ptprj phosphatase) as a major regulator of susceptibility 
to  intestinal  tumors  [18,  19].  Subsequently,  the  Ptprj 
phosphatase was shown to undergo loss of heterozygosity 
(LOH)  in  sporadic  human  CRC  [20].  Our  lab  has 
mapped  a  novel  major  CRC  susceptibility  locus  Ccs3, 
on mouse chromosome 3, which controls the differential 
susceptibility  of  A/J  (susceptible)  and  C57Bl/6J  (B6, 
resistant) strains to AOM-induced CRC [21]. 
On the other hand, CA-CRC can be modeled in mice 
using a single injection of either DMH or AOM followed 
by  intermittent  oral  administration  of  inflammation-
provoking  dextran  sulfate  (DSS)  [22].  This  treatment 
causes thickening of the mucosa, leukocytic infiltration 
and increased vascular density with permeabilization of 
the epithelial cell barrier. Several candidate genes have 
been implicated in CA-CRC in mice. For example, IL-2/
bb2 and IL-10 appear to play a protective role in CA-CRC, 
with  increased  incidence  of  colonic  inflammation  and 
adenocarcinomas in mice bearing inactivating mutations 
at  these  genes  [23,  24].  Likewise,  the  key  activator 
NF-κB  plays  a  critical  role  in  inflammation  and  CA-
CRC,  and  inactivation  of  the  NF-κB  activating  kinase 
or  TNFα,  the  upstream  activator  of  NF-κB)  results  in 
reduced tumor burden [25, 26]. While the aforementioned 
genes are crucial in CRC development no studies have 
been  undertaken  to  identify  low  penetrance  CA-CRC 
susceptibility loci in mice.
We  have  undertaken  genetic  studies  in  mice  to 
identify genetic loci that regulate susceptibility to CA-
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Figure 1: Pathology of AOM/Dss induced tumors in parental A/J and b6 mice.  (A) Mice were treated with a single AOM 
injection and 3 consecutive periods of DSS and were sacrificed at either week 3, 10, 14, or 19 post-injection.  H&E staining indicates that the 
animals developed grade 1 (B) or 3 inflammation (C) at 3 weeks (10 x magnification) in A/J and B6 mice, respectively.  This is followed by 
low grade dysplasias at 10 weeks (10 x (D) and 40 x (E) magnification, respectively) and (F) adenomas at 19 weeks (10 x magnification).  The 
arrows indicate sites of grade 3 inflammation in this panel.Oncotarget 2010; 1:  436 - 446 438 www.impactjournals.com/oncotarget
CRC, and that may be relevant to human cancer. Here, we 
show that A/J (susceptible) and B6 (resistant) mice show 
differential susceptibility to CA-CRC. This is controlled 
by a novel two-locus system on chromosome 9 (Ccs4) and 
14 with an additive effect.
rEsULts
A/J mice are susceptible to colitis-associated 
colorectal cancer
In  the  present  study,  we  investigated  whether  the 
two test strains, A/J and B6, differ in response to colitis-
associated colon cancer (CA-CRC) development. A/J and 
B6 mice were treated with a single dose of azoxymethane 
(AOM) followed by 3 subsequent treatments of dextran 
sulfate (DSS) (Fig. 1A). Colons were examined at 3, 10, 
14 or 19 weeks post-treatment and graded for degree of 
inflammation, and presence of hyperplastic lesions, and 
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Figure 2: susceptibility to cA-crc is not controlled by the Ccs3 locus. Tumor response of parental A/J and B6 mice and RCS 
strains BcA71, BcA72, and BcA87 mouse strains (encompassing the Ccs3 locus) to AOM induction (A) or AOM/DSS treatment (B). * p<0.01 
to B6; ** p<0.005 to B6.  (C) Haplotype of the above RCS for the Ccs3 locus.  Alleles at each locus are identified as ‘1’ in white (A/J) and ‘2’ 
in grey (B6).  The proximal boundary of the Ccs3 locus is defined by a resistant strain not shown in this figure. Oncotarget 2010; 1:  436 - 446 439 www.impactjournals.com/oncotarget
tumors. Inflammation was scored as described in [22]. At 
3-weeks post-treatment (Fig. 1B and C) grades 1 and 3 
inflammation scores were present in A/J and B6 colons, as 
defined by either a more scattered lymphocyte infiltration 
(Fig. 1B) or a larger extended infiltration with increased 
thickening of the mucosa (Fig. 1C). By 10 weeks post-
treatment,  B6  mice  generally  had  higher  inflammatory 
scores than A/J mice with low-grade dysplasia becoming 
apparent in some animals (Fig. 1D and E). At 10 weeks, B6 
mice demonstrated larger areas of extended inflammation, 
as noticed previously [22]. By 19 weeks, flat lesions with 
clearly  defined  circular  boundaries  were  identified  and 
scored as hyperplastic lesions. Tubular adenomas were 
also  detected  (>0.5  mm  diameter)  protruding  into  the 
lumen of the colon. The multiplicity and surface area of 
these tumors was used as the second and third quantitative 
traits in our genetic analyses. These lesions were mainly 
identified in the distal portion of the colon with scattered 
tumors being found occasionally in the proximal portion. 
After  14  weeks,  mice  showed  decreased  amounts  of 
inflammation with almost complete disappearance of the 
inflammation by week 19. On the other hand, A/J mice 
developed significantly more tubular adenomas relative 
to their B6 counterparts 14-19 weeks post initiation. An 
example of such lesions is shown in Fig. 1F after a 19-
week  treatment  period  showing  grade  3  inflammatory 
foci  (Fig.  1F,  arrows).  These  results  indicate  that  A/J 
mice, although seemingly less susceptible to initial DSS-
induced inflammation, nevertheless are highly susceptible 
to developing CA-CRC later on, compared to B6 mice. 
cA-crc susceptibility in A/J is independent of 
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Figure 3: segregation analysis of susceptibility to cA-crc induced by the AOM/Dss protocol. Distribution of tumor 
multiplicity (A), tumor surface area (B), and multiplicity of hyperplastic lesions (C) in A/J, B6, (A/J x B6)F1 and 148 segregating (A/J x B6)
F2 animals.  * p<0.05 to B6, ** p<0.0001 to B6.Oncotarget 2010; 1:  436 - 446 440 www.impactjournals.com/oncotarget
alleles at the Ccs3 locus
To quantify the differential susceptibility of the A/J 
and B6 mouse strains to CA-CRC, mice were subjected 
to the AOM/DSS protocol and their colons examined 19 
weeks  post-treatment  initiation  for  tumor  multiplicity. 
Results  in  Fig.  2B  show  that,  on  average,  A/J  mice 
developed a greater number of colon tumors than their 
B6  counterpart  (p<0.01). Although  the  absolute  tumor 
numbers in the A/J and B6 strains showed experimental 
variability,  we  consistently  observed  significant 
differences in tumor multiplicity between these two 
strains in independent experiments (Fig 2B, Fig. 3A). 
Inbred A/J and B6 mouse strains are either highly 
susceptible or fully resistant, to carcinogen-induced CRC, 
respectively [21]. This is determined by the Ccs3 locus 
on chromosome 3. Ccs3 was mapped as a monogenic 
trait  using  phenotype/genotype  correlation  in  a  set  of 
AcB/BcA recombinant congenic mouse lines [27]: these 
mice contain a small amount (12.5%) of DNA from one 
parent fixed as a set of discrete congenic segments on 
the background (87.5%) of the other parent. To assess a 
possible contribution of Ccs3 to differential susceptibility 
of  A/J  and  B6  mice  to  CA-CRC,  we  phenotyped  3 
informative recombinant congenic mouse strains, namely 
BcA71,  BcA72,  and  BcA87  that  carry  an A/J  derived 
Ccs3 chromosomal segment fixed on a B6 background 
(Fig. 2C). These 3 congenic lines responded to an 8-week 
AOM induction treatment by developing tumor numbers 
within  the  range  of  those  detected  in  the A/J  parents, 
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Figure 4: Identification and validation of a chromosome 9 CA-CRC susceptibility locus. (A) Genome-wide scan for AOM/
DSS-induced tumor multiplicity (black solid line) and AOM/DSS-induced tumor surface area (grey dashed line).  The genome scans identified 
a single significant hit (genome-wide significance threshold is 3.53) on chromosome 9 regulating tumor multiplicity (LOD 4.06) and tumor 
surface (LOD 4.96) following AOM/DSS treatment. Haplotype association validating the chromosome 9 association at peak markers D9Mit67 
with respect to tumor number (B) and rs13480182 with respect to tumor surface (C).  * p<0.01 to B6.  Oncotarget 2010; 1:  436 - 446 441 www.impactjournals.com/oncotarget
which were significantly higher than the parental B6 strain 
(p<0.005) (Fig. 2A). However, in the AOM-DSS protocol, 
the BcA71, BcA72, and BcA87 congenic lines showed 
low tumor numbers that were similar to those detected in 
parental B6 controls, and significantly different from those 
measured in A/J controls (Fig. 2B). These results suggest 
that the Ccs3 locus does not impact on the differential 
susceptibility of A/J and B6 mice to CA-CRC, and that the 
inter-strain difference for this trait is controlled by other 
genetic loci. 
Genetic analysis of the cA-crc susceptibility 
trait 
The mode of inheritance (monogenic vs polygenic) 
of the A/J vs B6 differential response to CA-CRC was 
investigated by segregation analysis in informative (A/J 
x B6)F1 and F2 mice. (A/J x B6)F1 and F2 mice were 
treated  with  the  AOM/DSS  protocol,  and  14  weeks 
later  colons  were  scored  for  tumor  multiplicity,  tumor 
surface area and number of hyperplastic lesions (Fig. 
3A, B and C). As indicated previously, the A/J parental 
mice displayed a significantly higher number of tumors 
per mouse (average = 38, p<0.0001) and a larger tumor 
surface  area  (average  =  128  mm2,  p<0.05)  relative  to 
the B6 mice (average = 9 for multiplicity, and 47 mm2 
for surface area). The (A/J x B6)F1 mice showed tumor 
numbers (average = 14) and surface area (58 mm2) that 
were  similar  to  that  of  the  B6  parent,  suggesting  that 
susceptibility  to  AOM/DSS-induced  CRC  is  inherited 
as a recessive trait in this cross. Tumor multiplicity and 
surface area were not normally distributed in the (A/J x 
B6)F2 animals with a preponderance of resistant animals, 
suggesting a simple genetic control for a recessive trait 
associated with susceptibility to CA-CRC. Gender had no 
significant effect on the phenotypic distribution (data not 
shown). Since development of CRC is usually preceded 
by  the  appearance  of  hyperplastic  lesions,  we  scored 
these lesions on the same 14-week treated colons. A/J 
mice showed approximately a two fold greater number of 
hyperplastic lesions (average = 9) compared to B6 mice 
(average = 4), whereas (A/J x B6)F1 and (A/J x B6)F2 
mice displayed a similar number of hyperplastic lesions 
(average = 8) relative to A/J mice, suggesting different 
patterns of inheritance and possibly different genetic 
controls for development of tumors vs hyperplasic lesions. 
A  genome-wide  scan  reveals  a  major  CA-CRC 
susceptibility locus on chromosome 9
To  further  investigate  the  genetic  determinant(s) 
of  CA-CRC  susceptibility,  a  whole  genome  scan  was 
performed  in  148  (A/J  x  B6)F2  mice  using  tumor 
multiplicity  and  surface  area  as  quantitative  traits.  In 
this  analysis,  genome-wide  significance  was  assessed 
at a LOD score >3.53. The results presented in Fig. 4A 
identify  one  significant  linkage  on  chromosome  9  that 
influences both tumor multiplicity and tumor area (LOD 
4.06 and LOD 4.96, respectively). These results indicate 
that development of CA-CRC in A/J vs B6 mouse strains 
is controlled by a genetic locus located on chromosome 9. 
We subsequently assessed the haplotype of the mice at the 
chromosome 9 peak markers to validate the directionality 
of the association with respect to tumor number (D9Mit67, 
36.8 Mb, Fig. 4B) and tumor area (rs13480182, 49.2 Mb, 
Fig.  4C). This  was  congruent  with  our  F1  distribution 
with mice inheriting two A/J alleles having significantly 
higher tumor numbers (n = 19, p<0.01) and tumor surface 
areas (A = 80 mm2, p<0.01) than mice inheriting at least 
one B6 allele. No differences were noted with respect to 
these measurements in mice inheriting either one or two 
B6 alleles (n = 11; A = 36 mm2 and n = 11; A = 37 mm2, 
respectively). We have attributed this locus the temporary 
designation  Ccs4,  for  colon  cancer  susceptibility  locus 
4. Ccs4 is unrelated to the Ccs3 locus on chromosome 
3  that  controls  susceptibility  to  AOM-induced  colon 
tumorigenesis  in  the  same  strains,  suggesting  distinct 
mechanistic basis for susceptibility to CRC (Ccs3) and 
CA-CRC (Ccs4).
Identification of a chromosome 14 Ccs4 modifier 
(A/J  X  B6)F2  mice  homozygote  for  A/J  alleles 
at  Ccs4  are  on  average  more  susceptible  to  CA-CRC 
with respect to tumor multiplicity and surface area than 
F2 mice heterozygous or homozygous for B6 alleles at 
this  locus.  However,  CA-CRC  susceptible  Ccs4a/a  F2 
mice  displayed  considerable  phenotypic  variance  with 
respect to tumor numbers and surface area, suggesting the 
possible contribution of additional genetic loci regulating 
tumor  multiplicity  on  the  permissive  Ccs4a/a genetic 
background. This was investigated by a two-dimensional 
genome scan, followed by assessing the contribution of 
A/J and B6 haplotypes to tumor numbers for all linkage 
peaks showing LOD scores >2. Both methods identified a 
single significant interaction of Ccs4 with a locus on the 
distal part of chromosome 14 (peak marker rs13482311, 
93.5 Mb). Haplotype analysis showed an additive and very 
strong effect of the two loci. Two-loci linkage analysis 
yielded LOD scores of 9.0 and 11.3 for the combined loci, 
explaining 24.5% and 29.7% of the phenotypic variation 
for  tumor  multiplicity  and  area,  respectively.  F2  mice 
that are homozygous for A/J alleles at both chromosome 
9  and  14  loci  display  tumor  multiplicity  and  surface 
areas comparable to the A/J controls (average = 31 vs 38 
and 154 mm2 vs 138 mm2, respectively) while F2 mice 
doubly  homozygous  for  B6  alleles  at  both  loci  show 
tumor numbers similar to that of the B6 parental controls 
(average = 9 vs 8 and 25 mm2 vs 47 mm2, for multiplicity 
and  surface  area,  respectively)  (Fig.  5).  These  results 
identify a two-locus system regulating susceptibility to Oncotarget 2010; 1:  436 - 446 442 www.impactjournals.com/oncotarget
CA-CRC in mice. 
DIscUssION
IBD, in the form of UC and CD, represent a major 
risk factor for CRC. The resulting CA-CRC occurs in a 
subset of IBD patients, which has prompted the search 
for  low  penetrance  tumor  susceptibility  genes,  thought 
to  mediate  progression  of  IBD  to  CA-CRC.  Mapping 
of these genes in humans can be complicated by the 
vast  genetic  and  environmental  heterogeneity  of  the 
populations  studied  and  hence  inbred  mice  have  been 
used to study CA-CRC whereby environmental factors 
and  genetic  backgrounds  can  be  fixed.  Chromosomal 
regions and individual loci identified by genetic analysis 
as regulating susceptibility to CA-CRC in mice represent 
valuable candidates for validation in cohorts of human 
clinical specimens. We have shown that A/J and B6 mice 
were susceptible and resistant, respectively to CA-CRC, 
as modeled using a single injection of AOM and repeated 
cycles of the inflammatory stimuli DSS. Using an (A/J 
x B6)F2 cross we mapped a novel two loci system on 
mouse chromosome 9 (Ccs4) and 14, whereby animals 
homozygous  for  either  A/J  or  B6  alleles  at  both  loci 
show  susceptibility/resistance  characteristics  similar 
to that of the parental strain, indicating that this 2-loci 
system explain a large portion of the phenotypic variance 
distinguishing the two parents. 
Both sporadic and CA-CRC arise from deregulation 
of the organized epithelial and stromal cells of the colon 
and harbor similar molecular alterations underlying CRC 
development  [28].  However,  the  timing  and  frequency 
of  these  molecular  events  are  different  with  mutations 
or LOH at p53 occurring early in CA-CRC while they 
arise late in sporadic CRC, and APC mutations are rare 
events in CA-CRC contrary to sporadic CRC [29]. This 
has led to speculation that appearance and progression 
of both sporadic CRC and CA-CRC may be influenced 
by different sets of genes. Results from our study support 
this  contention.  Indeed,  although A/J  is  susceptible  to 
both CRC and CA-CRC and although B6 is resistant to 
both pathologies, results obtained here with subsets of 
recombinant  congenic  strains  informative  for  the  Ccs3 
locus, together with formal genetic linkage analyses in 
segregating (A/J X B6)F2s have identified distinct and non-
overlapping genetic controls for both traits. Interestingly, 
the gene for the p105 NF-κB subunit maps within the 
5Mb physical interval delineating Ccs3 and p105-/- mice 
develop  spontaneous  intestinal  inflammation  similar  to 
human IBD [21, 30, data not shown]. It is tempting to 
speculate that the lack of association of Ccs3 with CA-
CRC in our studies indirectly suggests that it is not an 
NF-κB-mediated  differential  response  to  inflammatory 
stimulus  that  is  responsible  for A/J  vs  B6  inter-strain 
differences in susceptibility to CA-CRC. 
Scrutiny of published literature and the MGI (Mouse 
Genome Informatics) database reveal that Ccs4 overlaps 
a  previously  mapped  mouse  quantitative  trait  locus 
(QTL) that regulates response to infection in the form 
of differential control of tissue repair following injury. 
A locus regulating differential susceptibility of BALB/c 
(susceptible)  and  B6  (resistant)  mice  to  cutaneous 
leishmaniasis induced by infection with Leishmania 
major, and designated Lmr2, has been mapped to a ~10 
Mb interval on chromosome 9 that overlaps the genetic 
interval defined herein for the Ccs4 locus [31]. The genetic 
difference at Lmr2  is  expressed  as  a  vigorous  wound 
healing response required for lesion resolution following 
cutaneous infection with L. major. A number of candidate 
genes have been proposed for Lmr2 including Tirap, Fli1, 
           
  Chr 9 (Ccs4) =                                                    AA            AA           AA            BB            BB            BB
                                             A/J            B6
Chr 14 (rs13482311) =                                     AA            AB           BB            AA            AB            BB
0
20
40
60
80
100
120
140
160
180
200
220
240
260
0
5
10
15
20
25
30
35
40
45
50
55
           
  Chr 9 (Ccs4) =                                                     AA            AA           AA            BB            BB            BB
                                             A/J            B6
Chr 14 (rs13482311) =                                      AA            AB           BB            AA            AB            BB
*** **
*
*
A B
Figure 5
Figure 5:  Identification of a chromosome 14 modifier of the Ccs4 locus.  Genetic influence of a chromosome 14 locus (peak marker 
rs13482311) on tumor number (A) or tumor surface (B) for (A/J x B6)F2 mice homozygous for either A/J or B6 alleles at Ccs4 (D9Mit67 
with respect to tumor number and rs13480182 with respect to tumor surface).  Black boxes indicate mice that are either homozygous A/J or 
homozygous B6 across both loci.  * p<0.05, ** p < 0.001, *** p < 1 x 10-6.Oncotarget 2010; 1:  436 - 446 443 www.impactjournals.com/oncotarget
Il10ra, as well as members of the Mmp family, and Aplp2. 
Recently, a functional promotor polymorphism in the Fli1 
gene has been proposed as a strong candidate for Lmr2 
[31]. The possibility that the Ccs4-controlled differential 
susceptibility  to  CA-CRC  may  involve  differential 
response  to,  and  recovery  from  acute  inflammation-
induced tissue injury requires further investigation. Indeed, 
DSS treatment has been shown to cause permeabilization 
of the epithelial cell barrier resulting in increased cellular 
turnover to repair tissue damage, a response that may be 
under the control of Ccs4. It is also interesting to note that 
a similar two-locus system involving chromosome 9 and 
14 has been shown to regulate differential brain toxicity of 
human amyloid precursor protein expressed in transgenic 
129sv and FVB mice [32]. Although this two-locus system 
has been mapped in another strain pair, and with a low 
degree of resolution, it is nevertheless interesting to note 
that it regulates response to a toxic substance in the form 
of different degree to tissue damage.
The  Ccs4  confidence  interval  is  very  large  and 
stands at ~ 41Mb delineated by rs29835542/rs3723670 
with peak markers D9Mit67 (36.84 Mb) and rs13480182 
(49.23 Mb) for tumor multiplicity and area, respectively. 
The chromosome 14 locus maps to an ~ 30 Mb region 
with peak marker rs13482311 (93.5 Mb). The large size 
of  the  physical  intervals  for  the  two-loci  precludes  a 
detailed discussion of positional candidates for the genetic 
effects on CA-CRC. Nevertheless, using Gene Ontology 
classification (GO ontology browser) response to stimulus, 
tissue repair or cancer, several potential candidates arise 
for the Ccs4 locus. Interleukin 18 (IL18; position 50.4Mb) 
has been shown to modulate response to chemically-
induced colitis in mice [33]. Also, mice bearing a mutation 
in CASP12 (53.4Mb), an upstream effector of IL18, show 
increased  resistance  to  acute  inflammation,  but  also 
increased susceptibility to CA-CRC [34]. Retinoblastoma 
1 (Rb1; 73.6Mb), a known tumor suppressor, is known 
to be up-regulated in CRC samples compared to the 
normal  mucosa  [35].  The  formal  identification  of  the 
gene responsible for Ccs4 and associated QTLs on this 
portion of chromosome 14 will involve the creation and 
characterization  of  congenic  and  sub-congenic  lines  to 
narrow down the physical interval of Ccs4, as well as the 
formal evaluation of positional candidates, including the 
creation and testing of loss-of-function mutations in vivo.
The  Ccs4 locus is syntenic to regions found on 
human Chrs. 11, and 15 while the chromosome 14 locus is 
syntenic to regions of human chromosome 13. Although 
more than 30 human IBD loci have been identified with 
several mapping to the above chromosomes, none overlap 
with these loci. However, one human CRC susceptibility 
locus (11q23) falls within the current Ccs4 interval [6]. 
The 11q23 locus, associated with a gender-independent 
increased rectal cancer risk and a moderate colonic cancer 
risk, maps to a 60 kb region on human chromosome 11 
containing 3 ORFs (C11orf53, FLJ45803, LOC120376) 
and  a  nearby  gene  involved  in  humoral  immune 
response, POU2AF1 [36]. To date no non-synonymous 
polymorphisms have been identified within this locus and 
it does not appear to act in cis or trans-regulation with any 
other known CRC loci. 
Potential two-locus systems regulating pre-
disposition to colorectal cancer or to inflammatory bowel 
disease are extremely difficult and statistically challenging 
to  detect  in  human  GWAS  studies.  The  identification 
of  a  two-locus  system  in  mice  involving  chromosome 
9 (a possible homolog of the 11q23 human locus) and 
chromosome  14  provides  a  novel  candidate  region  of 
interest and interacting locus which can be readily tested 
in  available  GWAS  datasets  for  relevance  to  related 
human pathologies. 
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Ethics statement
This investigation has been conducted in accordance 
with the ethical standards and according to the Declaration 
of Helsinki and according to national and international 
guidelines  and  has  been  approved  by  the  authors’ 
institutional review board.
Animals
Inbred A/J, C57BL/6J (B6) and (A/J x B6)F1 mice 
were originally purchased from Jackson Laboratory (Bar 
Harbor, ME, USA). The AcB/BcA recombinant congenic 
strain  set  was  derived  from  a  double  backcross  (N3) 
between A/J and B6 parents at McGill University. The 
breeding scheme used for the derivation of these strains, 
and genotype data for these animals established for 625 
informative markers have been previously described [27]. 
The  (A/J  x  B6)F2  mice  were  generated  by  systematic 
brother-sister mating from a (A/J X B6)F1 hybrid. All mice 
were maintained at the Animal Care Facility of McGill 
University according to the guidelines of the Canadian 
Council on Animal Care. They were fed regular chow and 
water ad libitum. All experiments were conducted on mice 
that were a minimum of 8 weeks of age with a minimum 
of 5 mice per experimental group.  For the duration of 
the experiments mice were weighed/visually monitored 
a  minimum  of  twice  per  week  for  clinical  symptoms. 
Animals showing signs of discomfort were humanely 
sacrificed immediately. 
Azoxymethane-Induced crc 
The protocols for induction of colorectal cancer 
(CRC) by azoxymethane (AOM), the collection of colons, Oncotarget 2010; 1:  436 - 446 444 www.impactjournals.com/oncotarget
harvesting  of  tumors  and  normal  mucosa,  and  scoring 
methodology  were  previously  described  [21].  Briefly, 
10  week-old  mice  were  injected  with  the  carcinogen 
AOM (Sigma, St Louis, MO, USA) once per week for 
8 weeks (intra-peritoneal injections of 10 mg/kg). Mice 
were sacrificed at 19 weeks and the entire colon was fixed 
in  10%  phosphate-buffered  formalin  and  subsequently 
scored for the number of tumors and hyperplastic lesions. 
colitis-Associated crc
Induction  of  colitis-associated  colorectal  cancer 
(CA-CRC) was performed using a combination of AOM 
and dextran sulfate (DSS Salt Reagent Grade MW 36,000-
50,000, MP Biomedicals LCC, Solon, OH, USA). Mice 
were given a single injection of AOM (10 mg/kg i.p) on day 
zero, followed by three 4 day cycles of 3% DSS in drinking 
water. The first treatment was administered exactly a week 
after the AOM injection with each subsequent treatment 
17 days apart. Following the final DSS treatment, mice 
were given normal water until the end of the experiment 
(week 14 or 19). The 3% DSS solution was prepared by 
dissolving DSS in tap water and filter-sterilized using a 
0.22μm filter (Stericup® Filter Units, Milipore). Fresh 3% 
DSS was replenished every second day for the duration 
of treatment. Mice were monitored for DSS consumption 
during treatment (averaged per cage), with no significant 
differences being detected amongst the groups. At the 
end  of  experiment  the  mice  were  sacrificed  and  their 
colons  collected  and  tumors  enumerated  [21].  Tumors 
were measured using a clear transparency of 1 mm2 graph 
paper and total surface area determined based on the total 
number of squares overlaying the tumor (measured to the 
nearest 0.25 mm2).
Histology
The  mice  were  sacrificed  and  the  large  intestine 
(anus to cecum) was removed, washed in PBS and fixed 
in 10% phosphate-buffered formalin. Fixed tissues were 
dehydrated  in  ethanol  and  paraffin-embedded  prior  to 
sectioning (6 µm thickness). Samples were subsequently 
deparaffinized, mounted onto slides, stained with eosin 
and counterstained with hematoxylin, following standard 
histological procedures. Tumor grading and scoring of 
inflammation according to recommendations of Wirtz et 
al. [22] was performed by four pathologists (SJ, LG, VM, 
and SYC). Images were acquired using a Zeiss Axiovert 
instrument  (Zeiss  Canada,  Toronto,  ON,  Canada)  and 
processed using Adobe Photoshop (www.adobe.com) 
[21]. 
Linkage  and  Quantitative  Trait  Loci  (QTL) 
Mapping
Genomic tail DNA was extracted using a standard 
proteinase  K  treatment  [27].  The  genomic  DNA  was 
genotyped for a combined total of 142 single nucleotide 
polymorphisms  (SNPs)  and  microsatellite  markers 
with  coverage  at  approximately  25  Mb  intervals 
throughout the genome. SNPs and microsatellite markers 
polymorphic between A/J and B6 were chosen from the 
Mouse  Genome  Informatics  (http://www.informatics.
jax.org/)  database.  Initial  genotyping  was  performed 
using a custom-designed panel of SNPs and run using 
Sequenom iPlex Gold technology. Additional genotyping 
of  microsatellite  markers  was  done  by  either  standard 
(α-32P)-dATP labeling PCR reactions with separation on 
6%  denaturing  polyacrylamide  gels  or  non-radioactive 
PCR with subsequent separation on 2%-3% agarose gels 
and ethidium bromide staining. All QTL linkage analyses 
were  performed  using  R/qtl  and  the  EM  maximum 
likelihood  or  Hayley-Knott  algorithms  [37].  A  one-
dimensional scan was performed using the scan-one 
function  and  empirical  genome-wide  significance  was 
calculated by permutation testing (1000 tests). To search 
for  possible  two  gene  interactions,  a  two-dimensional 
scan was performed using the two-QTL model. Linkage 
analysis was conducted using tumor multiplicity and 
tumor surface area as independent phenotypic markers of 
differential susceptibility to CA-CRC. 
statistical Analysis
Data  is  expressed  as  the  mean  +/-  the  standard 
deviation  and  all  analyses  were  performed  using  the 
Student’s t-test. Results were considered significant if the 
p ≤ 0.05. 
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